Figure 11.

Low expression of MCM2, MCM4, MCM6, and MKI67 is associated with increased probability of relapse-free survival in luminal A breast cancer molecular subtype. Kaplan-Meier Plotter (Gyorffyet al, 2010).

The association between MCM2, MCM4, MCM6, and MKI67 expression and relapse-free survival of breast cancer patients, when they were stratified according to the molecular subtype, was studied using the online survival analysis tool Kaplan-Meier Plotter. MCM2, MCM4, MCM6, and MKI67 mRNA expression was stratified into high or low expression using the median mRNA expression level as the cutoff point. Low expression of each of MCM2, MCM4, MCM6, and MKI67 was associated with increased probability of relapse-free survival in luminal A breast cancer (P <.001). MCM6 and MCM2expression shows a significant association in luminal B breast cancer (P = .036 and .019, respectively), while MCM4 and MKI67expression does not (P = .12 and .095, respectively). None of the four markers show this association in HER2-positive and basal-like breast cancer.